(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Oric Pharmaceuticals's earnings in 2026 is -$135,214,000.On average, 18 Wall Street analysts forecast ORIC's earnings for 2026 to be -$148,816,847, with the lowest ORIC earnings forecast at -$178,547,091, and the highest ORIC earnings forecast at -$126,084,391. On average, 16 Wall Street analysts forecast ORIC's earnings for 2027 to be -$163,837,245, with the lowest ORIC earnings forecast at -$190,720,756, and the highest ORIC earnings forecast at -$129,345,194.
In 2028, ORIC is forecast to generate -$179,313,121 in earnings, with the lowest earnings forecast at -$212,024,670 and the highest earnings forecast at -$124,127,909.